#news #biotech Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint success

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint success .Investors punish Aeglea for missed rare disease secondaries, sending stock spiraling despite primary endpoint success
ntaylor
Mon, 12/06/2021 – 08:58

from FierceBiotech: Biotech https://ift.tt/3EwjcgP